VBL Therapeutics to Present at Upcoming Conferences in October
September 17 2018 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that the
company will provide a corporate overview at two events during
October, as detailed below. In addition the Company will
present data on its novel MOSPD2 program at ECTRIMS 2018 - European
Committee for Treatment and Research in Multiple Sclerosis.
Cantor Fitzgerald Global Healthcare Conference -
Presentation Details |
Date: |
Wednesday, October 3,
2018 |
Time: |
10:20am Eastern
Time |
Location: |
InterContinental New
York Barclay Hotel, New York |
Webcast: |
http://wsw.com/webcast/cantor7/vbl/ |
|
|
Chardan Gene Therapy Conference - Presentation
Details |
Date: |
Tuesday, October 9,
2018 |
Time: |
1:30pm Eastern
Time |
Location: |
Westin Grand Central
Hotel, New York |
Webcast: |
http://wsw.com/webcast/chard2/vbl/ |
|
|
ECTRIMS 2018 - Poster Presentation
Details: |
Abstract: |
MOSPD2: A Novel
Therapeutic Target for the Treatment of CNS Inflammation |
Session
title: |
Poster Session 2 |
Date: |
Thursday, October 11,
2018 |
Time: |
5:15-7:15pm Central
European Summer Time |
Poster
#: |
P871 |
Location: |
City Cube Messe
Berlin |
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. The Company’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
positioned to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”,
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
include, but are not limited to, statements regarding our product
candidates, including VB-111, including their clinical development,
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, and the risk that historical clinical trial results may
not be predictive of future trial results. A further list and
description of these risks, uncertainties and other risks can be
found in the Company’s regulatory filings with the U.S. Securities
and Exchange Commission, including in our annual report on Form
20-F for the year ended December 31, 2017, and subsequent filings
with the SEC. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. VBL Therapeutics undertakes no
obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024